In Table 10.3C of the article cited above, the median follow-up for VERTIS CV was inadvertently given as 3.5 years. The correct median follow-up is 3.0 years.

In addition, a composition error in Table 10.3C resulted in misaligned data for the row “Key secondary outcome” for DECLARE-TIMI 58, DAPA-CKD, VERTIS CV, and DAPA-HF. The complete secondary outcome data for each trial are as follows:

DECLARE-TIME 58: Death from any cause 0.93 (0.82–1.04); renal composite (≥40% decrease in eGFR rate <60 mL/min/1.73 m2, new ESRD, or death from renal or CV causes 0.76 (0.67–0.87).

DAPA-CKD: ≥50% decline in eGFR, ESKD, or death from renal cause 0.56 (0.45–0.68); death or HF hospitalization 0.71 (0.55–0.92); death from any cause 0.69 (0.53–0.88).

VERTIS CV: CV death or HF hospitalization 0.88 (0.75–1.03); CV death 0.92 (0.77–1.11); renal death, renal replacement therapy, or doubling of creatinine 0.81 (0.63–1.04).

DAPA-HF: CV death or HF hospitalization 0.75 (0.65–0.85).

The online version of the article ( has been updated with the correct data.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at